Gain practical insights into understanding and responding to the evolving needs of people living with CML, from diagnosis through treatment and beyond.
From 1 October 2026, Triptorelin 3.75mg (Diphereline®) will become available on the PBS for the treatment of a range of women’s health conditions, including breast cancer, endometriosis and uterine fibrosis.
As of 1 September 2026, nurse practitioners have been able to prescribe PBS-listed medicines for chronic myeloid leukaemia (CML) as a continuation of an existing therapy, where care is shared with a medical practitioner.
When is a rash more than just a rash? And what should you be looking for before a patient even tells you something has changed? Available exclusively to CNSA members, we encourage you to login and listen today!
Australia’s first National Gynaecological Cancer Roundtable has brought together more than 40 leaders from government, research, healthcare and the lived-experience community to identify shared priorities for improving outcomes for people affected by gynaecological cancers.
